Transcatheter Valve Replacement in Patients With Severe Mitral Valve Disease and Annular Calcification  by Himbert, Dominique et al.
J O U R N A L O F T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y V O L . 6 4 , N O . 2 3 , 2 0 1 4
ª 2 0 1 4 B Y T H E A M E R I C A N CO L L E G E O F C A R D I O L O G Y F O U N DA T I O N I S S N 0 7 3 5 - 1 0 9 7 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C .LettersTranscatheter Valve
Replacement in Patients
With Severe Mitral Valve
Disease and Annular
CalciﬁcationPatients with extensive mitral annular calciﬁcation
(MAC) may have an inoperable condition because of
insurmountable technical issues. Four cases have
suggested the feasibility of transcatheter mitral valve
replacement (TMVR) in these patients (1–4). We
report here the ﬁrst series of isolated transvenous
transseptal TMVR in native valves with severe MAC.
From October 2013 to April 2014, 4 patients who had
inoperable MAC but a life expectancy of longer than 1
year were recommended to undergo transvenous
TMVR. Patient #1 was a 72-year-old woman with prior
aortic valve replacement (AVR), tricuspid annulo-
plasty, and severe mitral stenosis who had been on
long-term corticosteroid therapy. This patient had se-
vere MAC (Figure 1, panel 1A), was in New York Heart
Association (NYHA) functional class IV, and had a
Society of Thoracic Surgeons (STS) risk score of 11%.
Patient #2 was a 74-year-old woman with cirrhosis,
chronic obstructive pulmonary disease, breast
cancer, and mitral stenosis. This patient had severe
MAC (Figure 1, panel 2A), was in NYHA functional
class IV, and had an STS score of 6%. Patient #3
was a 66-year-old woman with morbid obesity,
renal failure, prior AVR, post-endocarditis mitral
regurgitation (MR) with chordal rupture, and failure
of surgical valve repair due to extensive MAC (Figure
1, panel 3A). This patient was in NYHA functional
class IV and had an STS score of 19%. Patient #4 was a
45-year-old man who underwent chest radiation and
had AVR with bilateral mammary coronary artery
bypass grafting, myocardial infarction, and moderate
but circumferential MAC (Figure 1, panel 4A). This
patient was in NYHA functional class III due to severe
MR and had a moderate but circumferential MAC
(Figure 1, panel 4A), STS score of 7%. None of these
patients had a small left ventricular cavity or septal
bulge.The technique of transvenous TMVR in native
valves with severe MAC does not differ from that pre-
viously described for treatment of failedmitral surgery
(5). The Sapien XT transcatheter valves were 26 mm
(Patients #1 and #2) and 29 mm (Patients #3 and #4)
and mounted upside down on standard NovaFlex
catheters (Edwards Lifesciences, Irvine, California).
In 3 cases, prostheses were implanted in an adequate
position. In Patient #2, the 26-mm valve seemed too
high in the mitral annulus. Thus, a second 26-mm
valve was implanted into the ﬁrst valve in a more
appropriate ventricular position (Figure 1, panel 2B).
All of the prostheses appeared circular and fully
deployed (Figure 1, panels 1C to 4C). However, a grade
3þ MR was observed in patient 3 in front of a
protruding calciﬁcation, which improved to grade 2þ
after balloon dilation (Figure 1, panel 3D, arrow).
There was no left ventricular outﬂow tract
obstruction. Pre-discharge transthoracic echoc-
ardiography showed mean gradients ranging from 3
to 5 mm Hg and residual MR grade #1þ in 3 patients
and 2þ in 1 patient. On follow-up, ranging from 1 to 6
months, all patients were in NYHA functional class I
or II. Follow-up echocardiography showed a stable
position of the prosthesis, a mean transmitral
gradient <5 mm Hg, and trace MR in 2 patients at 2
and 6 months, respectively.
We found that circular MAC, even when moder-
ate, may offer enough support to allow stable
anchoring of the prosthesis with no regurgitation.
Of note, 3 of our patients had already undergone
AVR, which may have contributed to improving the
rigidity of the mitral annulus. In contrast, several
patients were rejected for TMVR because the calci-
ﬁcation was restricted to the posterolateral part of
the annulus, which is more common. Severe pre-
existing MR does not preclude a good result of
TMVR.
TMVR is feasible via an isolated transvenous
transseptal approach. Previous reports have described
transapical approaches in 2 cases, transseptal access
combined with a transapical externalization of the
wire in 1 case, and an open left atrial approach in 1
case. All of these approaches implied direct cardiac
access and its potential complications. Here, the
transvenous procedures were all successful. However,
this technique is demanding and requires speciﬁc
FIGURE 1 Patient Series
Images are for patients 1 to 4 in respective columns. (1A, 2A, 3A, 4A) Computed tomog-
raphy of mitral annular calciﬁcations. (1B) Three-dimensional transesophageal echocardi-
ography of valve implantation within the mitral annulus. (2B, 3B, 4B) Fluoroscopy of valve
implantation within the mitral annulus. (1C, 2C, 3C, 4C) Computed tomography post-
implantation. (1D) Three-dimensional echocardiography post-implantation. (2D, 3D, 4D)
Two-dimensional echocardiography post-implantation.
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2558training in transseptal catheterization and complex
mitral valve interventions.
A circular deployment of the balloon-expandable
device is obtained despite the saddle-shape geome-
try of the mitral annulus, and the tissue cushioning
surrounding the annulus may avoid the incidence
of paraprosthetic regurgitation. However, extensive
and protruding calciﬁcation may lead to peripro-
sthetic leaks.
The initial data on follow-up are encouraging;
however, potential concerns may relate to the risks
of atrial displacement and valve thrombosis.
This preliminary series suggests that transvenous
TMVR is feasible in inoperable patients with severe
mitral valve disease and MAC, particularly in those
with previous AVR, and may provide early and
midterm clinical and hemodynamic improvement. It
opens a discussion, and many issues are still to be
resolved. Further conﬁrmation may have an impor-
tant impact given the prevalence of severe MAC in
elderly patients and the technical difﬁculties of sur-
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13:1205–6.Effectiveness of
Antitachycardia Pacing
for Recurrent Ventricular
Tachycardia in ARVCIn their prospective study of the North American
Arrhythmogenic Right Ventricular Cardiomyopathy
(ARVC) Registry, Link et al. (1) reported a 92% success
rate with antitachycardia pacing (ATP) in terminating
recurrent ventricular tachycardia (VT) in 48 patients
with an implantable cardioverter-deﬁbrillator (ICD)
who experienced a total of 489 sustained mono-
morphic VT episodes. The beneﬁt of ATP appeared
to be independent of the VT cycle length.
